KD-026 是具有口服活性的、肠细胞特异性的微粒体甘油三酯转移蛋白 (MTP)抑制剂,IC50为 8.0 nM。KD-026 在糖尿病2型中有研究的价值。
产品描述
KD-026, a microsomal triglyceride transfer protein (MTP) inhibitor(IC50 = 8.0 nM), is used in type 2 diabetes studies.
体外活性
KD-026 shows inhibitory effect against apolipoprotein B (IC50 = 9.6 nM) but no effect on apolipoprotein A1 secretion in Caco-2 cells[1].
体内活性
In rats, KD-026 (30 mg/kg) reduced postprandial lipids by 50% (ED50 = 7 mg/kg)[1].
Cas No.
913541-47-6
分子式
C31H25F3N2O4
分子量
546.54
别名
SLx 4090;KD026;SLx-4090;SLx4090
储存和溶解度
DMSO:55 mg/ml (100.63 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years